Suppr超能文献

沙利度胺用于造血干细胞移植后组织细胞肉瘤的治疗。

Thalidomide for the treatment of histiocytic sarcoma after hematopoietic stem cell transplant.

作者信息

Abidi Muneer H, Tove Isaacson, Ibrahim Rami B, Maria Dan, Peres Edward

机构信息

Division of Hematology and Oncology, Barbara Ann Karmanos Cancer Institute, Wayne State University, Detroit, Michigan 48109, USA.

出版信息

Am J Hematol. 2007 Oct;82(10):932-3. doi: 10.1002/ajh.20913.

Abstract

Histiocytic sarcoma (HS) is a rare neoplasm of uncertain etiology. Most recently, the diagnostic criteria for this entity have been revised with inclusion of diagnostic modalities such as immunohistochemical and cytogentic techniques. HS tends to have an aggressive clinical course and presents with systemic symptoms of fever, weight loss, adenopathy, hepatosplenomegly, rash, and pancytopenia. Thalidomide is a promising agent that may exert a therapeutic benefit in HS. We report a case of a 48-year-old female with HS who presented with fever, weight loss, fatigue, generalized anasarca, and pancytopenia. She underwent multi-agent chemotherapy followed by matched unrelated hematopoietic stem cell transplant. Her disease recurred and thalidomide therapy was started, with her overall disease burden significantly reduced as measured radiographically.

摘要

组织细胞肉瘤(HS)是一种病因不明的罕见肿瘤。最近,该实体的诊断标准已修订,纳入了免疫组织化学和细胞遗传学技术等诊断方法。HS往往具有侵袭性临床病程,表现为发热、体重减轻、淋巴结病、肝脾肿大、皮疹和全血细胞减少等全身症状。沙利度胺是一种有前景的药物,可能对HS有治疗益处。我们报告一例48岁患有HS的女性,表现为发热、体重减轻、疲劳、全身性水肿和全血细胞减少。她接受了多药化疗,随后进行了匹配的非亲缘造血干细胞移植。她的疾病复发,开始使用沙利度胺治疗,影像学测量显示其总体疾病负担显著减轻。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验